MVA-BN-Brachyury-TRICOM

AXP000185.1 · Cancer vaccine

Platform
MVA-BN (with fowlpox boost)
Targets
TBXT
Originator
Bavarian Nordic
Sponsor
Bavarian Nordic

Names

NameTypeSource
MVA-BN-Brachyury-TRICOMpreferred namecurator
BN-Brachyurycodecurator
FPV-Brachyury-TRICOMcodencit
MVA-BN-Brachyurycodencit
MVA Brachyury-TRICOM ambiguoussynonymncit

Virus

Role
Vaccine vector
Family
Poxviridae
Virus
vaccinia virus (NCBI Taxonomy 10245)
Strain
MVA-BN prime; fowlpox (FPV-Brachyury) boost
Replication
non replicating
Modifications
brachyury and TRICOM cassettes in MVA-BN
Transgenes
TBXT, CD80, ICAM1, CD58
Route
subcutaneous
Source
evidence

Cross-references

NCI Thesaurus
C148400
FDA UNII
GD1ZWN2I2Y

Approvals

No regulatory approval recorded.

Clinical trials (6)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT05445882N-803 Alone or in Combination With BN-Brachyury Vaccine or Bintrafusp Alfa (M7824) for Participants With Castration Resistant Prostate CancerWithdrawnPhase 22024-04-012024-04-010Castration Resistant Prostate Cancer
NCT04134312A Phase 1 Open Label Trial of Intravenous Administration of MVA-BN-Brachyury Vaccine in Patients With Advanced CancerCompletedPhase 12020-01-082021-01-1213Solid Metastatic Tumor
NCT04020094Perioperative Atezolizumab With MVA-BN-Brachyury and PROSTVAC For Intermediate-Risk And High-Risk Localized Prostate CancerWithdrawnPhase 22019-11-202021-04-090Prostate Adenocarcinoma
NCT03595228BN Brachyury and Radiation in ChordomaCompletedPhase 22018-10-312021-12-1029Chordoma
NCT03493945Phase I/II Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, N-803 and Epacadostat (QuEST1)CompletedPhase 1/22018-05-012024-10-0859Advanced Solid Tumor; Metastatic Castration-resistant Prostate Cancer; Non-metastatic Castration-resistant Prostate Cancer; Prostate Cancer; Prostate Neoplasm; Solid Tumor
NCT03349983Safety and Tolerability Trial (MVA-BN-Brachyury/FPV-Brachyury)CompletedPhase 12018-01-082020-06-1311Safety Issues
Unconfirmed matches (2)

Trials that mention one of the names in a weaker way (a code only in the title, a short or ambiguous name). Not counted above.

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditionsMatched by
NCT04296942BN-Brachyury, Entinostat, Adotrastuzumab Emtansine and M7824 in Advanced Stage Breast Cancer (BrEAsT)TerminatedPhase 12021-05-042021-10-221Breast Cancer; HER2+ Breast Cancer; Hormone Receptor Negative Breast Cancer; Metastatic Breast Cancer; Triple Negative Breast Cancername in title: BN-Brachyury
NCT02179515Safety and Tolerability of a Modified Vaccinia Ankara (MVA)-Based Vaccine Modified to Express Brachyury and T-cell Costimulatory Molecules (MVA-Brachyury-TRICOM)CompletedPhase 12014-06-282017-04-0638Breast Cancer; Lung Cancer; Ovarian Cancer; Prostate Cancer; Tumors (Others)intervention named: MVA Brachyury-TRICOM

Recent changes

No changes recorded in its trials yet.

Clinical papers

PubMedTitleJournalYearLinked by
PMID 42498485Durable responses to triplet immunotherapy targeting TGF-β, PD-L1, and tumor antigen, with an IL-15 receptor superagonist in mismatch repair proficient castration-resistant prostate cancer.Journal for immunotherapy of cancer2026cited by trial NCT03493945
PMID 38985843A phase 2 study of a brachyury-targeting vaccine in combination with radiation therapy for the treatment of advanced chordoma.Cancer2024name in abstract: MVA-BN-Brachyury
PMID 33602696Differential combination immunotherapy requirements for inflamed (warm) tumors versus T cell excluded (cool) tumors: engage, expand, enable, and evolve.Journal for immunotherapy of cancer2021cited by trial NCT03493945
PMID 34266694Chordoma: Current status, problems, and future directions.Current problems in cancer2021cited by trial NCT03595228
PMID 34479925Phase 1 open-label trial of intravenous administration of MVA-BN-brachyury-TRICOM vaccine in patients with advanced cancer.Journal for immunotherapy of cancer2021cited by trial NCT04134312
PMID 31876334Phase I Trial of a Modified Vaccinia Ankara Priming Vaccine Followed by a Fowlpox Virus Boosting Vaccine Modified to Express Brachyury and Costimulatory Molecules in Advanced Solid Tumors.The oncologist2020cited by trial NCT03349983
PMID 30227893Quick efficacy seeking trial (QuEST1): a novel combination immunotherapy study designed for rapid clinical signal assessment metastatic castration-resistant prostate cancer.Journal for immunotherapy of cancer2018cited by trial NCT03493945

Other papers

Preclinical studies, reviews and other papers that name it.

PubMedTitleJournalYearLinked by
PMID 33747894Improving the Odds in Advanced Breast Cancer With Combination Immunotherapy: Stepwise Addition of Vaccine, Immune Checkpoint Inhibitor, Chemotherapy, and HDAC Inhibitor in Advanced Stage Breast Cancer.Frontiers in oncology2020name in abstract: BN-Brachyury

NIH grants

ProjectTitleOrganisationPIYearsLinked by
ZIABC010598Human Immune Responses to Tumor Antigens for Cancer ImmunotherapyDIVISION OF BASIC SCIENCES - NCISCHLOM, JEFFREY2012–2025name in abstract: MVA-BN-Brachyury-TRICOM
ZIABC010425Strategies for Cancer Immunotherapy Clinical TrialsDIVISION OF BASIC SCIENCES - NCISCHLOM, JEFFREY2009–2023name in abstract: MVA-BN-Brachyury-TRICOM
ZIABC011865Breast and Other Carcinoma Clinical Trials Using ImmunotherapiesDIVISION OF BASIC SCIENCES - NCIGATTI-MAYS, MARGARET2019–2020name in abstract: MVA-BN-Brachyury

Notes

MVA-BN-Brachyury prime with FPV-Brachyury-TRICOM boosts (NCIt C148402), encoding brachyury (TBXT) and TRICOM; phase 1/2 at the NCI in chordoma and other solid tumours. NCIt also holds a separate earlier concept 'MVA Brachyury-TRICOM' (C116777) whose relationship to this construct is unclear; that name is listed as an ambiguous alias.

How to cite

MVA-BN-Brachyury-TRICOM (AXP000185.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000185.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.